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Abstract
Objectives—To estimate the association of pregravid body mass index (BMI), independent of 3-
hour oral glucose tolerance test (OGTT) results, with pregnancy outcome.
Study Design—In this secondary analysis of a cohort of women with untreated mild gestational
glucose intolerance, defined as 50g glucose loading test between 135 and 199 mg/dL and fasting
glucose <95 mg/dL, we modeled the association between pregravid BMI, OGTT results, and both
pregnancy complications and neonatal adiposity.
Results—Among 1250 participants, both pregravid BMI and glucose at hour 3 of the OGTT
were associated with increased risk of gestational hypertension. Maternal pregravid BMI was also
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positively associated with LGA, and both maternal BMI and fasting glucose were associated with
birth-weight z-score and neonatal fat mass.
Conclusions—Among women with untreated mild gestational glucose intolerance, pregravid
BMI is associated with increased gestational hypertension, birth weight and neonatal fat mass,
independent of OGTT values.
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Introduction
Both maternal obesity1-5 and gestational diabetes6 (GDM) are associated with an increased
risk of adverse pregnancy outcomes. Mothers with these conditions face higher rates of
gestational hypertension, preeclampsia, and cesarean delivery7. Infants born to these
mothers are at increased risk for macrosomia, birth trauma, hypoglycemia and admission to
the neonatal intensive care unit. Moreover, these infants are at increased risk for obesity in
later life8.
Treatment of GDM can reduce complications9, 10. Obesity is also associated with adverse
pregnancy outcome, but the predictive value of maternal pregravid body mass index (BMI)
independent of glucose intolerance is not well-defined. If maternal pregravid BMI is
associated with adverse outcomes independent of glucose tolerance, then glucose tolerant,
obese women may require extra surveillance and/or treatment to mitigate their risk. If, on
the other hand, glucose tolerance mediates associations between obesity and adverse
outcomes, then obese women with normal glucose tolerance could be considered as low risk
and treated as such.
We sought to estimate the association of maternal pregravid BMI, independent of glucose
tolerance, with adverse pregnancy outcomes. We therefore measured the independent
association of pregnancy outcome with pregravid BMI and parameters of the 3-hour oral
glucose tolerance test (OGTT) in a cohort of women with untreated mild gestational glucose
intolerance.
Materials and methods
We performed a secondary analysis of women with untreated mild gestational glucose
intolerance. Participants were women randomized to no treatment in the previously reported
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Maternal-Fetal Medicine Units Network multicenter randomized trial of treatment for mild
gestational diabetes (GDM), as well as women in the associated observational cohort,
comprised of women with a 50-gram glucose screen ≥ 135 mg/dL who did not meet criteria
for gestational diabetes. 9 All the women who participated in the study provided written
informed consent. The study was approved by the human subjects committee at each
participating center.
To be eligible for participation in the primary study, women had to be between 24 weeks 0
days and 30 weeks 6 days gestation and have a 50-gram glucose loading test screen between
135 and 199 mg/dL. Eligible women underwent diagnostic testing with a 100-gram 3-hour
OGTT. Women with normal fasting values (< 95 mg/dL) but at least 2 OGTT values
exceeding established thresholds (1h 180 mg/dL, 2h 155 gm/dL, 3h 140 mg/dL) were
randomized to treatment for mild GDM or usual care. In addition, women with normal
OGTT results were followed in an observational cohort. Participants in the observational
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cohort were frequency matched at each participating center to the GDM group by body mass
index < or ≥ 27 kg/m2 and race/ethnicity. By design, providers were blinded to OGTT
results for women who were randomized to the usual care and observational groups;
therefore, clinical care was unrelated to OGTT results. Further details of the methodology of
the study have been described elsewhere. 9 Women were excluded from the primary study if
they had any of the following conditions: preexisting diabetes, an abnormal result on a
glucose screening test < 24 wks, or prior GDM; history of stillbirth, multifetal gestation,
asthma, or chronic hypertension; were taking corticosteroids; had a known fetal anomaly, or
were likely to have an imminent preterm delivery.
For the current analysis, we excluded women missing data on pregravid BMI (N=110),
leaving 414 women with mild GDM who were randomized to usual care and 836 who were
enrolled in the observational cohort. We used maternal pregravid weight and measured
height to calculate pregravid BMI in kg/m2. Maternal weight was abstracted from the
prenatal record or obtained by patient report, and height was measured at the time of the 3-
hour OGTT.
The primary outcome of the parent study was a composite outcome of perinatal mortality,
hypoglycemia, hyperbilirubinemia, neonatal hyperinsulinemia, or birth trauma9. Gestational
hypertension was defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood
pressure ≥ 90 mm Hg or more on two occasions at least 4 hours apart, or one elevated blood-
pressure value subsequently treated with medication. Preeclampsia was defined as elevation
in blood pressure, as defined for gestational hypertension, with proteinuria (≥ 300 mg of
protein / 24-hour collection or dipstick ≥2+ if 24-hour collection not available) or with AST
≥ 70 U/L or platelet count < 100,000/L. Birth weight z-score was calculated using U.S.
singleton birth weight percentiles for gestational age from 1994 to 199611. Large for
gestational age (LGA) birth weight was defined as > 90% for gestational age, and small for
gestational age (SGA) was defined as birth weight < 10% for gestational age. To estimate
neonatal fat mass12, trained research staff measured the infant’s length, head and upper mid-
arm circumferences, and flank skin-fold shortly after the infant’s birth.
We used Spearman correlation coefficient to measure the association between 3-hour OGTT
parameters and maternal pregravid BMI. We then used logistic regression to measure the
association between maternal pregravid BMI, OGTT results and the following pregnancy
outcomes: composite neonatal outcome, gestational hypertension or preeclampsia,
preeclampsia alone, LGA, and SGA. We further used linear regression to model the
association between maternal pregravid BMI, OGTT results and birth weight z-score11 and
neonatal fat mass. All regression models included parity, maternal age and race/ethnicity,
maternal pregravid BMI and all four OGTT values. To illustrate the magnitude of
differences associated with a range of maternal pregravid BMI, we present predicted
probabilities (figure 1) and z-scores and fat mass (figure 2) for each outcome as a function
of maternal BMI for a hypothetical multiparous white woman with population mean values
for age (27.9 years) and for the oral glucose tolerance test (fasting: 85.3, 1h: 166.5, 2h:
144.3, 3h: 117.1). The Shieh-O’Brien approximation was used for power calculations13. All
the statistical analyses were performed using SAS statistical software (SAS Institute, Cary,
NC) and R (www.r-project.org).
Results
Of the 1250 women eligible for inclusion in our analysis, the majority was Hispanic
(54.2%). The mean maternal age was 27.9 years, and 34% were nulliparous (Table 1).
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Maternal pregravid BMI correlated with fasting 3-hour OGTT results (r=0.16, p <.001).
BMI was also associated with the 1-hour value on the 3-hour OGTT and inversely
associated with 3-hour value. We found correlations among all four 3-hour OGTT
parameters (all p ≤ 0.005), with the strongest correlations among post-load values (Table 2).
In logistic regression analyses including both maternal pregravid BMI and 3-hour OGTT
parameters, we found that maternal BMI was predictive of outcome independent of OGTT
(Table 3). Both maternal BMI and 3-hour OGTT were positively associated with the
composite outcome of gestational hypertension or preeclampsia (OR per 5 BMI units: 1.29,
95%CI 1.10-1.51; OR per 10 mg/dL 3h glucose: 1.08, 95%CI 1.01-1.17). Maternal
pregravid BMI was positively associated with LGA birth weight (OR per 5 BMI units 1.21,
95%CI 1.03-1.41) and negatively associated with SGA birth weight (OR per 5 BMI units .
77, 95%CI .60-.96). We found no statistically significant associations between maternal
BMI or 3-hour OGTT parameters and preeclampsia or composite neonatal outcome.
Maternal BMI was strongly associated with both birth weight z-score and neonatal fat mass.
We further found that fasting glucose and 2-hour glucose values were associated with
greater birth weight z-score, and fasting glucose values were associated with greater fat
mass. Predicted probabilities of gestational hypertension, preeclampsia, LGA and SGA, as
well as birth weight z-score and fat mass, for a white, multiparous mother aged 27.9 years
with mean OGTT results, are presented in Figures 1 and 2.
A post-hoc power analysis was performed to determine the odds ratio for which our sample
provided 80% power with an alpha of 0.05 to detect a statistically significant association
between BMI and outcome given the prevalence of preeclampsia (4.4%) and composite
outcome (34.0%) in our population. We estimated we had 80% power to detect a 1.43-fold
OR of preeclampsia and a 1.18-fold OR of composite outcome per 5 BMI units.
Comment
In a secondary analysis of a cohort of women with 50-gram glucose loading test screen
between 135 and 199 mg/dL and normal fasting glucose, we found that elevated maternal
pregravid BMI was associated with hypertensive complications, infant birth weight z-score
and fat mass, independent of 3-hour OGTT results. These findings suggest that elevated
maternal pregravid BMI is an independent risk factor for adverse birth outcomes and
neonatal adiposity, with the caveat that our cohort was limited to women with mild
gestational glucose intolerance, and therefore may not be generalizable to women with more
severe hyperglycemia.
Our findings confirm and extend earlier work linking maternal BMI and glucose tolerance
with pregnancy outcomes. In the HAPO study (N=23,316), Metzger et al14 assessed
pregnancy outcomes among women with fasting glucose < 105 mg/dL and 2-hour, 75g
OGTT < 200 mg/dL at 24 to 32 weeks’ gestation. They found maternal BMI at study
enrollment was directly associated with LGA, primary cesarean section, cord serum c-
peptide > 90th percentile, intensive neonatal care, preeclampsia and neonatal adiposity.
These associations were attenuated with adjustment for fasting glucose and mean arterial
pressure at the time of the OGTT visit, but remained statistically significant for all outcomes
except intensive neonatal care. Other authors have similarly found associations between
body mass index and adverse perinatal outcome, independent of glucose tolerance15-22.
Our finding that 3-hour OGTT values were not associated with adverse outcome reflects our
modeling approach. The purpose of our analysis was to determine whether maternal BMI is
associated with adverse pregnancy outcomes, independent of glucose tolerance. As
expected, we found that the 4 values on the 3-h OGTT are correlated. The inclusion of
correlated values in a multiple regression model increases the confidence intervals for each
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variable and increases p values, reducing the likelihood of detecting an association between
each 3-hour OGTT value and pregnancy outcome. This analysis answers a specific clinical
question: if two women have the same 3-hour OGTT result, but one has a higher BMI, how
much more should a clinician be concerned about the higher BMI patient? This information
can assist clinicians in risk-stratifying patients based on pregravid BMI. This is distinct from
assessing whether two women with the same BMI, but different values at single value of the
OGTT, without considering other OGTT values, have different clinical outcomes. Indeed,
other analyses in this cohort, and in other populations, have found that individual fasting and
post-load glucose values are associated with increased risk of adverse outcome23, 24.
Treatment of gestational glucose intolerance reduces adverse outcomes, including
macrosomia and gestational hypertensive complications9, 10, 25. The independent association
of maternal BMI with these outcomes suggests that glucose tolerant overweight or obese
women are similarly at risk for adverse outcomes, and treatment strategies are needed to
reduce this risk. Recent randomized controlled trials among overweight women have had
mixed results26-28. In some cases, intervention participants have improved adherence to
dietary guidelines or increased physical activity without a difference in gestational weight
gain or metabolic parameters29-31. A small pilot study (N=50) among non-diabetic, obese
women found that intensive nutrition consultation reduced gestational weight gain, with a
trend toward lower rates of gestational diabetes and pregnancy-induced hypertension32.
Birth weights were marginally lower in the intervention group. A recent cluster-randomized
trial in Finland enrolled 399 women who were euglycemic in early pregnancy but at high
risk of GDM. The physical activity, diet and weight gain intervention reduced infant birth
weight by 133g (95% CI -231 to -35) and rates of LGA from 19.7 to 12.1 % (p=0.04).
Additional large randomized trials, some of which are underway33, are needed to confirm or
refute the utility of lifestyle intervention to improve outcomes among glucose-tolerant
overweight or obese pregnant women and their infants.
Strengths of our secondary analysis include standardized, prospective assessment of glucose
tolerance, maternal height, and obstetrical outcomes in the parent trial. The multicenter
design of the parent trial included women from 14 centers in the United States, increasing
generalizability. Nevertheless, our findings must be interpreted in the context of the study
design. This was a secondary analysis of participants in a clinical trial, and enrollment was
limited to women with moderately elevated glucose loading test results but a fasting glucose
< 95mg/dL. Our results are therefore only generalizable to women with mild glucose
intolerance. Because the study enrollment criteria constrained glucose parameters, but not
body mass index, we were more likely to detect an association with maternal BMI than with
OGTT parameters. This sample bias may contribute to our findings that 3-hour OGTT
parameters did not independently predict pregnancy outcomes. Further, observational cohort
participants were frequency-matched to GDM participants by maternal obesity status,
defined as BMI <27 vs. ≥ 27 kg/m2. These selection criteria may further affect
generalizability of our results. In addition, pregravid BMI was obtained from chart
abstraction or maternal recall, and thus may be subject to misclassification. If heavier
women were likely to underreport pregravid BMI34, this misclassification would bias our
results toward the null. Nevertheless, we found statistically significant associations between
pregravid BMI and both hypertensive complications and extremes of birth weight. Further,
the low prevalence of preeclampsia in our cohort reduced our power to detect associations
between BMI and preeclampsia in our cohort. However, point estimates obtained in our
sample suggest that BMI is more strongly associated with gestational hypertension than with
preeclampsia. Finally, we measured associations between pregravid BMI and seven clinical
outcomes, but we did not adjust for multiple comparisons. The rationale for this approach
was that our goal was to estimate the strength of associations between maternal body mass
index and obstetrical complications, independent of maternal glycemia, rather than to test
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whether a specific a priori hypothesis was true or false. Nevertheless, it is possible that some
of the observed associations were due to chance.
In conclusion, we found a direct association between maternal pregravid BMI and both
gestational hypertension and neonatal adiposity, independent of oral glucose tolerance test
parameters. Clinical trials are needed to determine whether dietary and lifestyle
interventions among women with elevated pregravid BMI can reduce gestational
hypertension and mitigate the intergenerational transmission of obesity.
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Predicted probability* of primary outcome, gestational hypertension, preeclampsia, SGA
and LGA, by prepregnancy maternal BMI.
Predicted probabilities of pregnancy outcome presented for a hypothetical multiparous white
women with mean values for age (27.9) and OGTT values (fasting: 85.3, 1h: 166.5, 2h:
144.3, 3h: 117.1). Models include parity, maternal age, race/ethnicity, maternal pregravid
BMI and all four OGTT values.
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Predicted birth weight z-score and fat mass by prepregnancy maternal BMI.
Predicted birth weight z-score and neonatal fat mass presented for a hypothetical
multiparous white women with mean values for age (27.9) and OGTT values (fasting: 85.3,
1h: 166.5, 2h: 144.3, 3h: 117.1). Models include parity, maternal age, race/ethnicity,
maternal pregravid BMI and all four OGTT values.
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Table 1











Normal BMI (<25 kg/m2) 546 (43.7)
Overweight BMI (25-<30 kg/m2) 410 (32.8)
Obese BMI (≥30 kg/m2) 294 (23.5)
Mean (SD)
BMI (kg/m2) 26.6 (5.6)
Age, mean (SD) 27.9 (5.6)
Fasting glucose 85.3 (5.9)
1h glucose, mg/dL 166.5 (30.2)
2h glucose 144.3 (29.5)
3h glucose 117.1 (28.5)
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Table 2
Correlations* among maternal pregravid BMI and parameters of the 3-hour 100 gram oral glucose tolerance
test.
Oral glucose tolerance test (OGTT)
Fasting 1-hour 2-hour 3-hour
Pregravid BMI 0.159 0.068 0.011 -0.086
<.0001 0.016 0.687 0.002
3-hour OGTT 0.089 0.293 0.439
0.002 <.0001 <.0001
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